Dataset Information
Responder and non-responder proteomic and phosphoproteomic profiles to ATRA/Valproic acid before treatment
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Q Exactive HF
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Blood Cell, Blood
DISEASE(S): Acute Leukemia
SUBMITTER: 
Maria Hernandez-Valladares
LAB HEAD: Maria Hernandez-Valladares
PROVIDER: PXD024110 | Pride | 2021-09-10
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| AT1-pre_x1.raw | Raw | |||
| AT1-pre_x2.raw | Raw | |||
| AT1-pre_x3.raw | Raw | |||
| AT10-pre_x1.raw | Raw | |||
| AT10-pre_x2.raw | Raw |
Items per page: 1 - 5 of 116 |
Publications
Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid.
Cancers 20210429 9
All-trans retinoic acid (ATRA) and valproic acid (VP) have been tried in the treatment of non-promyelocytic variants of acute myeloid leukemia (AML). Non-randomized studies suggest that the two drugs can stabilize AML and improve normal peripheral blood cell counts. In this context, we used a proteomic/phosphoproteomic strategy to investigate the in vivo effects of ATRA/VP on human AML cells. Before starting the combined treatment, AML responders showed increased levels of several proteins, espe ...[more]
